4/18
08:04 am
mrns
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its price target lowered by analysts at Truist Financial Co. from $25.00 to $10.00. They now have a "buy" rating on the stock.
Low
Report
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its price target lowered by analysts at Truist Financial Co. from $25.00 to $10.00. They now have a "buy" rating on the stock.
4/17
03:45 pm
mrns
Lost Money on Marinus Pharmaceuticals, Inc.(MRNS)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
Medium
Report
Lost Money on Marinus Pharmaceuticals, Inc.(MRNS)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
4/16
01:19 pm
mrns
Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study [Yahoo! Finance]
Medium
Report
Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study [Yahoo! Finance]
4/16
11:15 am
mrns
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Medium
Report
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
4/16
08:13 am
mrns
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) was downgraded by analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating. They now have a $2.00 price target on the stock, down previously from $20.00.
Medium
Report
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) was downgraded by analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating. They now have a $2.00 price target on the stock, down previously from $20.00.
4/10
10:19 am
mrns
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $28.00 price target on the stock.
Low
Report
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $28.00 price target on the stock.
4/5
04:00 pm
mrns
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Medium
Report
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
4/4
05:35 pm
mrns
GRIN, WOOF and MRNS are among after hour movers [Seeking Alpha]
High
Report
GRIN, WOOF and MRNS are among after hour movers [Seeking Alpha]
3/27
08:41 am
mrns
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review
Low
Report
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review
3/27
08:21 am
mrns
One Biosciences Welcomes Dr. Scott Braunstein and Dr. Vincent Miller to its Board of Directors [Yahoo! Finance]
Low
Report
One Biosciences Welcomes Dr. Scott Braunstein and Dr. Vincent Miller to its Board of Directors [Yahoo! Finance]
3/26
08:13 am
mrns
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Medium
Report
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
3/7
01:53 pm
mrns
Marinus Pharmaceuticals Inc (MRNS) Reports Full Year and Q4 2023 Financial Results [Yahoo! Finance]
Neutral
Report
Marinus Pharmaceuticals Inc (MRNS) Reports Full Year and Q4 2023 Financial Results [Yahoo! Finance]
3/7
11:16 am
mrns
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/7
08:25 am
mrns
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its "market perform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $9.00 price target on the stock.
Medium
Report
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its "market perform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $9.00 price target on the stock.
3/6
11:04 pm
mrns
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
3/6
10:31 am
mrns
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $24.00 price target on the stock.
Medium
Report
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $24.00 price target on the stock.
3/6
08:10 am
mrns
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Low
Report
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
3/5
04:10 pm
mrns
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
Medium
Report
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
3/5
04:01 pm
mrns
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Low
Report
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
3/1
08:58 am
mrns
Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings Estimates [Yahoo! Finance]
Medium
Report
Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings Estimates [Yahoo! Finance]
2/21
07:00 am
mrns
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
Low
Report
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
2/20
07:21 am
mrns
Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024 [Yahoo! Finance]
Medium
Report
Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024 [Yahoo! Finance]
2/20
07:00 am
mrns
Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
Medium
Report
Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
2/16
04:00 pm
mrns
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Medium
Report
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
1/31
11:26 am
mrns
Global Orphan Drugs Research Analysis Report 2023: Growing Approvals of Innovative Orphan Drugs Propel Market Expansion, Biologics Lead the Way - Forecasts to 2034 [Yahoo! Finance]
Low
Report
Global Orphan Drugs Research Analysis Report 2023: Growing Approvals of Innovative Orphan Drugs Propel Market Expansion, Biologics Lead the Way - Forecasts to 2034 [Yahoo! Finance]